GlaxoSmithKline Consumer Healthcare Ltd posted a net profit of ₹130 crore for the quarter ended June 30, up 9 per cent from ₹119.96 crore in the corresponding quarter previous fiscal.
Net sales were up 8 per cent to ₹922 crore.
In a statement, the company said growth has been consistent in all categories at an all-India level led by West region and also it saw growth business from rural regions, on the back of coverage expansion and strong activation.
The company’s board of directors appointed Sangeeta Talwar as an Independent Director. Zubair Ahmed MD GSK Consumer Healthcare said that the company has been delivering consistent growth ahead of the category which is significant in a scenario where consumption pattern is being impacted by inflation.
“Our sciences based products with its superior value, continue to remain relevant for our large consumer base. “As a market leader we are also growing the category with successful launches of new products which are driving up consumption experiences. Our focused access strategy ensures that consumption and penetration has been the enabler for growth.
“Customer-driven innovations and clutter breaking marketing based on sharp consumer insights will continue to be our driving force in the coming months to bring in more consumers closer to the product,” he added.